Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
Christopher R. King,Debra Freeman,Irving D. Kaplan,Donald B. Fuller,Giampaolo Bolzicco,Sean P. Collins,Robert J. Meier,Jason Wang,Patrick A. Kupelian,Michael L. Steinberg,Alan W. Katz +10 more
Reads0
Chats0
TLDR
PSA relapse-free survival rates after SBRT compare favorably with other definitive treatments for low and intermediate risk patients, and the current evidence supports consideration of S BRT among the therapeutic options for these patients.About:
This article is published in Radiotherapy and Oncology.The article was published on 2013-11-01 and is currently open access. It has received 394 citations till now. The article focuses on the topics: PSA Failure & Androgen deprivation therapy.read more
Citations
More filters
Journal ArticleDOI
Organisation of Prostate Cancer Services in the English National Health Service.
Ajay Aggarwal,Ajay Aggarwal,Julie Nossiter,Paul Cathcart,Paul Cathcart,J van der Meulen,J van der Meulen,J. Rashbass,Noel W. Clarke,Heather Payne +9 more
TL;DR: The organisational survey of the NPCA has provided a comprehensive assessment of the structure and function of specialist MDTs in England and the availability of prostate cancer procedures and services.
Journal ArticleDOI
Cost-Effectiveness of Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy: a Critical Review
TL;DR: SRS and SBRT are likely to be cost-effective management strategies across a large variety of treatment sites and techniques, however, rigorous model validation techniques are lacking in these modeling studies.
Journal ArticleDOI
Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer.
Michael Wahl,Martina Descovich,Erin Shugard,Dilini Pinnaduwage,Atchar Sudhyadhom,Albert J. Chang,Mack Roach,Alexander Gottschalk,Josephine Chen +8 more
TL;DR: It is found that interfraction anatomical variations can lead to a substantial increase in delivered rectal doses during prostate stereotactic body radiotherapy, which may help mitigate the impact of daily organ motion and reduce the risk of rectal toxicity.
Journal ArticleDOI
Stereotactic body radiation therapy for prostate cancer-a review.
TL;DR: Prostate cancer SBRT may be more cost effective than CFRT using intensity modulated radiation therapy (IMRT) or proton based radiation therapy.
Journal ArticleDOI
Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer: assessment of patient-reported quality of life.
Marta Scorsetti,Filippo Alongi,Elena Clerici,Tiziana Comito,Antonella Fogliata,Cristina Iftode,Pietro Mancosu,Piera Navarria,Giacomo Reggiori,Stefano Tomatis,Elisa Villa,Luca Cozzi +11 more
TL;DR: Stereotactic body radiotherapy (SBRT) treatment of prostate with RapidArc and high-intensity photon beams resulted to be well tolerated by patients with mild toxicity profiles and good patient-reported quality of life perception for the first year after treatment.
References
More filters
Journal ArticleDOI
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
TL;DR: Significant late bladder and rectal toxicities from SBRT for prostate cancer are infrequent and the current evidence supports consideration of stereotactic body radiotherapy among the therapeutic options for localized prostate cancer.
Journal ArticleDOI
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.
TL;DR: The outcomes after high-dose hypofractionation were acceptable in the entire cohort of patients treated with the schedule of 70 at 2.5 Gy/fraction and the 5-year nadir + 2 ng/mL rate was 83% (95% confidence interval, 79–86%).
Journal ArticleDOI
Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results
TL;DR: In this paper, the feasibility and toxicity of stereotactic hypofractionated accurate radiotherapy (SHARP) for localized prostate cancer were evaluated in a Phase I/II trial with 40 patients.
Journal ArticleDOI
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.
Himu Lukka,Charles Hayter,Jim A. Julian,Padraig Warde,W. James Morris,Mary Gospodarowicz,Mark Levine,Jinka Sathya,Richard Choo,Hugh M. Prichard,Michael Brundage,Winkle Kwan +11 more
TL;DR: This study was designed as a noninferiority investigation with a predefined tolerance of −7.5%.
Journal ArticleDOI
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
David P. Dearnaley,Isabel Syndikus,Georges Sumo,M. Bidmead,D. Bloomfield,Catharine H. Clark,Annie Gao,Shama Hassan,Alan Horwich,Robert Huddart,Vincent Khoo,Peter Kirkbride,Helen Mayles,P. Mayles,O. Naismith,Chris Parker,Helen Patterson,Martin J. Russell,Christopher D Scrase,C. South,John Staffurth,Emma Hall +21 more
TL;DR: A pre-planned preliminary safety analysis of side-effects in stages 1 and 2 of a randomised trial comparing standard and hypofractionated radiotherapy seems equally well tolerated as conventionally fractionated treatment at 2 years.
Related Papers (5)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David P. Dearnaley,Isabel Syndikus,Helen Mossop,Vincent Khoo,Alison Birtle,D. Bloomfield,John Graham,Peter Kirkbride,John P Logue,Zafar Malik,Julian Money-Kyrle,Joe M. O'Sullivan,Miguel Panades,Chris Parker,Helen Patterson,Christopher D Scrase,John Staffurth,Andrew Stockdale,Jean Tremlett,M. Bidmead,Helen Mayles,O. Naismith,C. South,Annie Gao,Clare Cruickshank,Shama Hassan,Julia Pugh,Clare Griffin,Emma Hall +28 more
Fractionation and protraction for radiotherapy of prostate carcinoma
David J. Brenner,Eric J. Hall +1 more